首页 | 本学科首页   官方微博 | 高级检索  
检索        

三维适形放疗治疗局部晚期非小细胞肺癌的疗效
引用本文:Cao JZ,Ou GF,Liang J,Lü JM,Zhou ZM,Chen DF,Xiao ZF,Feng QF,Zhang HX,Wang LH,Yin WB.三维适形放疗治疗局部晚期非小细胞肺癌的疗效[J].中华肿瘤杂志,2011,33(7):529-534.
作者姓名:Cao JZ  Ou GF  Liang J  Lü JM  Zhou ZM  Chen DF  Xiao ZF  Feng QF  Zhang HX  Wang LH  Yin WB
作者单位:1. 山西省肿瘤医院放疗科,太原,030013
2. 北京协和医学院肿瘤医院肿瘤研究所放射治疗科,中国医学科学院,100021
基金项目:吴阶平医学基金会-卫生部"肿瘤精确放射治疗网络研究" 临床科研协作研究基金
摘    要:目的 评价三维适形放疗治疗局部晚期非小细胞肺癌(NSCLC)的疗效.方法 527例局部晚期NSCLC患者中,253例接受三维适形放疗,274例接受常规放疗.三维适形放疗组中,接受化放综合治疗者159例(62.8%).放射剂量为50~59 Gy者49例, 60 Gy者127例,>60 Gy者77例.常规放疗组中,接受放化综合治疗者127例(46.4%).放射剂量为50~59 Gy者75例,60 Gy者151例,>60 Gy者48例.结果 三维适形放疗组患者的1、3、5年总生存率分别为73.3%、26.1%和14.4%,中位生存时间为20.1 个月;常规放疗组患者的1、3、5年总生存率分别为61.0%、13.8%和8.0%,中位生存时间为15.6 个月(P=0.002).三维适形放疗组患者的1、3、5年肿瘤专项生存率分别为79.0%、33.3%和20.8%,常规放疗组患者分别为65.1%、16.7%和11.2%(P<0.001).三维适形放疗组患者的1、3、5年局部区域控制率分别为71.6%、34.3%和31.0%;常规放疗组患者分别为57.3%、22.1%和19.2%(P=0.002).多因素分析结果显示,KPS评分、治疗前血红蛋白、放疗方法和近期疗效是NSCLC患者总生存和肿瘤专项生存的独立影响因素,三维适形放疗组的总生存率和肿瘤专项生存率较常规放疗组显著提高(OR分别为0.762和0.680,均P<0.01).两组患者放射性食管炎和放射性肺炎的发生率差异无统计学意义(P>0.05).结论 采用三维适形放疗技术,能够提高局部晚期NSCLC患者的生存率.
Abstract:
Objective To compare the treatment results of three-dimensional conformal radiotherapy (3D-CRT) and conventional radiotherapy (2D) for patients with locally advanced non-small-cell lung cancer (NSCLC). Methods Five hundred and twenty seven patients with stage Ⅲ NSCLC treated between Jan 2000 and Dec 2006 were included in this study. Among them, 253 cases were treated with 3D-CRT, and 274 with conventional radiotherapy. In the 3D group,159(62.8%)patients ceceived chemoradiotherapy, 77 with total radiotherapy dose of >60 Gy, 49 with 50-60 Gy. In the 2D group, 127(46.4%)patients received chemoradiotherapy,48 with total radiotherapy dose of >60 Gy,75 with 50-60 Gy. Results The 1-, 3-, 5-year overall survival rates(OS)and median survival time for patients treated with 3D-CRT were 73.3%, 26.1%, 14.4% and 20.1 months, respectively, and that of patients treated with 2D radiotherapy were 61.0%, 13.8%, 8.0% and 15.6 months, respectively (P=0.002). The 1-, 3-, 5-year cause-specific survival rates(CSS) were 79.0%, 33.3%, and 20.8% for the 3D group and 65.1%, 16.7%, 11.2%, respectively, for the 2D group (P=0.000). The 1-, 3-, and 5-year locoregional control rates were 71.6%, 34.3% and 31.0% for patients treated with 3D radiotherapy and 57.3%, 22.1% and 19.2%, respectively, for patients treated with 2D treatment(P=0.002). The results of multivariate analysis showed that 3D-CRT, KPS, clinical tumor response and pretreatment hemoglobin level were independently associated with increased OS and CSS. No statistically significant differences were found between the radiation complications in the two groups. Conclusions The results of our study demonstrate that 3D-conformal radiotherapy improves the survival rate in patients with stage Ⅲ NSCLC compared with that of 2D radiation therapy.

关 键 词:  非小细胞肺  放射疗法  三维适形放疗  疗效  预后

Therapeutic efficacy of three-dimensional conformal radiation therapy for patients with locally advanced non-small cell lung cancer
Cao Jian-zhong,Ou Guang-fei,Liang Jun,Lü Ji-ma,Zhou Zong-mei,Chen Dong-fu,Xiao Ze-fen,Feng Qin-fu,Zhang Hong-xing,Wang Lü-hua,Yin Wei-bo.Therapeutic efficacy of three-dimensional conformal radiation therapy for patients with locally advanced non-small cell lung cancer[J].Chinese Journal of Oncology,2011,33(7):529-534.
Authors:Cao Jian-zhong  Ou Guang-fei  Liang Jun  Lü Ji-ma  Zhou Zong-mei  Chen Dong-fu  Xiao Ze-fen  Feng Qin-fu  Zhang Hong-xing  Wang Lü-hua  Yin Wei-bo
Institution:CAO Jian-zhong,OU Guang-fei,LIANG Jun,L(U) Ji-ma,ZHOU Zong-mei,CHEN Dong-fu,XIAO Ze-fen,FENG Qin-fu,ZHANG Hong-xing,YIN Wei-bo
Abstract:Objective To compare the treatment results of three-dimensional conformal radiotherapy (3D-CRT) and conventional radiotherapy (2D) for patients with locally advanced non-small-cell lung cancer (NSCLC). Methods Five hundred and twenty seven patients with stage Ⅲ NSCLC treated between Jan 2000 and Dec 2006 were included in this study. Among them, 253 cases were treated with 3D-CRT, and 274 with conventional radiotherapy. In the 3D group,159(62.8%)patients ceceived chemoradiotherapy, 77 with total radiotherapy dose of >60 Gy, 49 with 50-60 Gy. In the 2D group, 127(46.4%)patients received chemoradiotherapy,48 with total radiotherapy dose of >60 Gy,75 with 50-60 Gy. Results The 1-, 3-, 5-year overall survival rates(OS)and median survival time for patients treated with 3D-CRT were 73.3%, 26.1%, 14.4% and 20.1 months, respectively, and that of patients treated with 2D radiotherapy were 61.0%, 13.8%, 8.0% and 15.6 months, respectively (P=0.002). The 1-, 3-, 5-year cause-specific survival rates(CSS) were 79.0%, 33.3%, and 20.8% for the 3D group and 65.1%, 16.7%, 11.2%, respectively, for the 2D group (P=0.000). The 1-, 3-, and 5-year locoregional control rates were 71.6%, 34.3% and 31.0% for patients treated with 3D radiotherapy and 57.3%, 22.1% and 19.2%, respectively, for patients treated with 2D treatment(P=0.002). The results of multivariate analysis showed that 3D-CRT, KPS, clinical tumor response and pretreatment hemoglobin level were independently associated with increased OS and CSS. No statistically significant differences were found between the radiation complications in the two groups. Conclusions The results of our study demonstrate that 3D-conformal radiotherapy improves the survival rate in patients with stage Ⅲ NSCLC compared with that of 2D radiation therapy.
Keywords:Carcinoma  non-small cell lung  Radiotherapy  Three dimensional radiation therapy  Therapeutic efficacy  Prognosis
本文献已被 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号